Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts

Blood, Vol. 112, Issue 10, 4314-4317, November 15, 2008
This Article
Right arrow Abstract
Right arrow Full Text
Services
Right arrow Email this article to a friend
Right arrow Alert me to new issues of the journal
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef

G6PD deficiency, absence of {alpha}-thalassemia, and hemolytic rate at baseline are significant independent risk factors for abnormally high cerebral velocities in patients with sickle cell anemia
Blood Bernaudin et al. 112: 4314

Supplemental materials for: Bernaudin et al

Transcranial Color Doppler imaging (TCDI) was performed using imaging equipment (Acuson, GE Medical Systems, Hitachi). Using the temporal and suboccipital approach, time averaged maximum mean flow velocity (TAMMX) was obtained in the distal internal carotid artery, the middle cerebral artery from the MCA/ACA bifurcation to the peripheral location, the initial anterior cerebral artery, the posterior cerebral artery and the basilar artery. No angle correction was used. The envelope of the waveform was traced manually or electronically depending on the quality of the waveform. Accordingly to Adams (STOP study), velocities were considered as abnormally high when TAMMX was at least higher than 200 cm/sec in MCA, ACA or ICA. TCD was performed once a year or once a trimester when conditional (170–199 cm/sec). However, contrary to the STOP study, since August 2001, we have initiated transfusion programs after the first abnormal TCD because a young girl followed since birth in our center with abnormal high velocities detected at the age of 1.5 years had a stroke at the age of 1.6 years just before the TCD control and the initiation of the transfusion program. Since this observation, we decided to begin the TP after the first abnormal TCD.





This Article
Right arrow Abstract
Right arrow Full Text
Services
Right arrow Email this article to a friend
Right arrow Alert me to new issues of the journal
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020